BsmI vitamin D receptor genotypes influence the efficacy of antiresorptive treatments in postmenopausal osteoporotic women. A 1-year multicenter, randomized and controlled trial

Stefano Palomba, Francesco Orio, Tiziana Russo, Angela Falbo, Achille Tolino, Francesco Manguso, Vincenzo Nunziata, Pasquale Mastrantonio, Gaetano Lombardi, Fulvio Zullo

Research output: Contribution to journalArticle

Abstract

Vitamin D receptor (VDR) gene polymorphisms could be considered one of the factors influencing the efficacy of the anti-osteoporotic treatments. In this multicenter, prospective, randomized and controlled trial we evaluated whether BsmI vitamin D receptor (VDR) genotypes influence the efficacy of antiresorptive treatment regimes (administered alone or in combination) in postmenopausal osteoporotic women. Using restriction endonuclease, we identified the BsmI VDR polymorphism in 1,100 postmenopausal women with osteoporosis. The women were randomized, taking account of genotype, into five treatment groups: (1) alendronate (Aln, 10 mg/day) plus raloxifene (Rlx, 60 mg/day); (2) Aln plus hormone replacement therapy (HRT, 0.625 mg/day conjugated equine estrogens plus 2.5 mg/day medroxyprogesterone acetate); (3) Aln alone; (4) HRT alone; and (5) Rlx alone. Lumbar-spine bone mineral density (BMD) and bone turnover markers were measured at study entry and after 1 year of treatment. Using the general linear model (GLM) repeated-measures procedure, the means of BMD and bone turnover markers significantly differed from baseline after a period of treatment. In particular, the mean change from baseline for BMD was -0.034 (95% confidence interval [CI]: -0.037 to -0.031, P

Original languageEnglish
Pages (from-to)943-952
Number of pages10
JournalOsteoporosis International
Volume16
Issue number8
DOIs
Publication statusPublished - Jul 2005

Fingerprint

Calcitriol Receptors
Randomized Controlled Trials
Genotype
Bone Density
Bone Remodeling
Conjugated (USP) Estrogens
Bone and Bones
Alendronate
Medroxyprogesterone Acetate
DNA Restriction Enzymes
Hormone Replacement Therapy
Therapeutics
Osteoporosis
Linear Models
Spine
Confidence Intervals
Genes

Keywords

  • Bisphosphonates
  • Clinical trials
  • Menopause
  • Osteoporosis
  • SERMs
  • Treatments
  • Vitamin D

ASJC Scopus subject areas

  • Medicine(all)

Cite this

BsmI vitamin D receptor genotypes influence the efficacy of antiresorptive treatments in postmenopausal osteoporotic women. A 1-year multicenter, randomized and controlled trial. / Palomba, Stefano; Orio, Francesco; Russo, Tiziana; Falbo, Angela; Tolino, Achille; Manguso, Francesco; Nunziata, Vincenzo; Mastrantonio, Pasquale; Lombardi, Gaetano; Zullo, Fulvio.

In: Osteoporosis International, Vol. 16, No. 8, 07.2005, p. 943-952.

Research output: Contribution to journalArticle

Palomba, Stefano ; Orio, Francesco ; Russo, Tiziana ; Falbo, Angela ; Tolino, Achille ; Manguso, Francesco ; Nunziata, Vincenzo ; Mastrantonio, Pasquale ; Lombardi, Gaetano ; Zullo, Fulvio. / BsmI vitamin D receptor genotypes influence the efficacy of antiresorptive treatments in postmenopausal osteoporotic women. A 1-year multicenter, randomized and controlled trial. In: Osteoporosis International. 2005 ; Vol. 16, No. 8. pp. 943-952.
@article{a9966943140941349ae4241735991ebf,
title = "BsmI vitamin D receptor genotypes influence the efficacy of antiresorptive treatments in postmenopausal osteoporotic women. A 1-year multicenter, randomized and controlled trial",
abstract = "Vitamin D receptor (VDR) gene polymorphisms could be considered one of the factors influencing the efficacy of the anti-osteoporotic treatments. In this multicenter, prospective, randomized and controlled trial we evaluated whether BsmI vitamin D receptor (VDR) genotypes influence the efficacy of antiresorptive treatment regimes (administered alone or in combination) in postmenopausal osteoporotic women. Using restriction endonuclease, we identified the BsmI VDR polymorphism in 1,100 postmenopausal women with osteoporosis. The women were randomized, taking account of genotype, into five treatment groups: (1) alendronate (Aln, 10 mg/day) plus raloxifene (Rlx, 60 mg/day); (2) Aln plus hormone replacement therapy (HRT, 0.625 mg/day conjugated equine estrogens plus 2.5 mg/day medroxyprogesterone acetate); (3) Aln alone; (4) HRT alone; and (5) Rlx alone. Lumbar-spine bone mineral density (BMD) and bone turnover markers were measured at study entry and after 1 year of treatment. Using the general linear model (GLM) repeated-measures procedure, the means of BMD and bone turnover markers significantly differed from baseline after a period of treatment. In particular, the mean change from baseline for BMD was -0.034 (95{\%} confidence interval [CI]: -0.037 to -0.031, P",
keywords = "Bisphosphonates, Clinical trials, Menopause, Osteoporosis, SERMs, Treatments, Vitamin D",
author = "Stefano Palomba and Francesco Orio and Tiziana Russo and Angela Falbo and Achille Tolino and Francesco Manguso and Vincenzo Nunziata and Pasquale Mastrantonio and Gaetano Lombardi and Fulvio Zullo",
year = "2005",
month = "7",
doi = "10.1007/s00198-004-1800-5",
language = "English",
volume = "16",
pages = "943--952",
journal = "Osteoporosis International",
issn = "0937-941X",
publisher = "Springer London",
number = "8",

}

TY - JOUR

T1 - BsmI vitamin D receptor genotypes influence the efficacy of antiresorptive treatments in postmenopausal osteoporotic women. A 1-year multicenter, randomized and controlled trial

AU - Palomba, Stefano

AU - Orio, Francesco

AU - Russo, Tiziana

AU - Falbo, Angela

AU - Tolino, Achille

AU - Manguso, Francesco

AU - Nunziata, Vincenzo

AU - Mastrantonio, Pasquale

AU - Lombardi, Gaetano

AU - Zullo, Fulvio

PY - 2005/7

Y1 - 2005/7

N2 - Vitamin D receptor (VDR) gene polymorphisms could be considered one of the factors influencing the efficacy of the anti-osteoporotic treatments. In this multicenter, prospective, randomized and controlled trial we evaluated whether BsmI vitamin D receptor (VDR) genotypes influence the efficacy of antiresorptive treatment regimes (administered alone or in combination) in postmenopausal osteoporotic women. Using restriction endonuclease, we identified the BsmI VDR polymorphism in 1,100 postmenopausal women with osteoporosis. The women were randomized, taking account of genotype, into five treatment groups: (1) alendronate (Aln, 10 mg/day) plus raloxifene (Rlx, 60 mg/day); (2) Aln plus hormone replacement therapy (HRT, 0.625 mg/day conjugated equine estrogens plus 2.5 mg/day medroxyprogesterone acetate); (3) Aln alone; (4) HRT alone; and (5) Rlx alone. Lumbar-spine bone mineral density (BMD) and bone turnover markers were measured at study entry and after 1 year of treatment. Using the general linear model (GLM) repeated-measures procedure, the means of BMD and bone turnover markers significantly differed from baseline after a period of treatment. In particular, the mean change from baseline for BMD was -0.034 (95% confidence interval [CI]: -0.037 to -0.031, P

AB - Vitamin D receptor (VDR) gene polymorphisms could be considered one of the factors influencing the efficacy of the anti-osteoporotic treatments. In this multicenter, prospective, randomized and controlled trial we evaluated whether BsmI vitamin D receptor (VDR) genotypes influence the efficacy of antiresorptive treatment regimes (administered alone or in combination) in postmenopausal osteoporotic women. Using restriction endonuclease, we identified the BsmI VDR polymorphism in 1,100 postmenopausal women with osteoporosis. The women were randomized, taking account of genotype, into five treatment groups: (1) alendronate (Aln, 10 mg/day) plus raloxifene (Rlx, 60 mg/day); (2) Aln plus hormone replacement therapy (HRT, 0.625 mg/day conjugated equine estrogens plus 2.5 mg/day medroxyprogesterone acetate); (3) Aln alone; (4) HRT alone; and (5) Rlx alone. Lumbar-spine bone mineral density (BMD) and bone turnover markers were measured at study entry and after 1 year of treatment. Using the general linear model (GLM) repeated-measures procedure, the means of BMD and bone turnover markers significantly differed from baseline after a period of treatment. In particular, the mean change from baseline for BMD was -0.034 (95% confidence interval [CI]: -0.037 to -0.031, P

KW - Bisphosphonates

KW - Clinical trials

KW - Menopause

KW - Osteoporosis

KW - SERMs

KW - Treatments

KW - Vitamin D

UR - http://www.scopus.com/inward/record.url?scp=23744498096&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23744498096&partnerID=8YFLogxK

U2 - 10.1007/s00198-004-1800-5

DO - 10.1007/s00198-004-1800-5

M3 - Article

C2 - 15739035

AN - SCOPUS:23744498096

VL - 16

SP - 943

EP - 952

JO - Osteoporosis International

JF - Osteoporosis International

SN - 0937-941X

IS - 8

ER -